↓ Skip to main content

Cochrane Database of Systematic Reviews

Omalizumab for asthma in adults and children

Overview of attention for article published in Cochrane database of systematic reviews, January 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
2 news outlets
policy
1 policy source
twitter
31 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
488 Dimensions

Readers on

mendeley
586 Mendeley
citeulike
2 CiteULike
Title
Omalizumab for asthma in adults and children
Published in
Cochrane database of systematic reviews, January 2014
DOI 10.1002/14651858.cd003559.pub4
Pubmed ID
Authors

Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters, Parameswaran Nair

Abstract

Asthma is a respiratory (airway) condition that affects an estimated 300 million people worldwide and is associated with significant morbidity and mortality. Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E (IgE). It is called an 'anti-IgE' drug. IgE is an immune mediator involved in clinical manifestations of asthma. A recent update of National Institute for Health and Care Excellence (NICE) guidance in 2013 recommends omalizumab for use as add-on therapy in adults and children over six years of age with inadequately controlled severe persistent allergic IgE-mediated asthma who require continuous or frequent treatment with oral corticosteroids.

Twitter Demographics

The data shown below were collected from the profiles of 31 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 586 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
Japan 2 <1%
Tunisia 1 <1%
South Africa 1 <1%
Mexico 1 <1%
Unknown 579 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 81 14%
Student > Master 80 14%
Researcher 65 11%
Student > Ph. D. Student 57 10%
Student > Postgraduate 37 6%
Other 133 23%
Unknown 133 23%
Readers by discipline Count As %
Medicine and Dentistry 240 41%
Nursing and Health Professions 36 6%
Agricultural and Biological Sciences 26 4%
Pharmacology, Toxicology and Pharmaceutical Science 23 4%
Biochemistry, Genetics and Molecular Biology 22 4%
Other 81 14%
Unknown 158 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2022.
All research outputs
#916,608
of 22,500,788 outputs
Outputs from Cochrane database of systematic reviews
#2,014
of 12,264 outputs
Outputs of similar age
#11,490
of 310,169 outputs
Outputs of similar age from Cochrane database of systematic reviews
#24
of 161 outputs
Altmetric has tracked 22,500,788 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,264 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.1. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,169 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 161 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.